At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 26 enrolled
Drug / intervention
AGB101 220 mg +1 moredrug
Likely dose
AGB101 220 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Network-Level Mechanisms for Preclinical Alzheimer's Disease Development
In Brief
A Phase 2 clinical trial evaluating AGB101 220 mg and Placebo for APOE 4. Completed, enrolled 26 participants across 1 site.
Detailed Summary
The purpose of this project is to test the hypothesis that AGB101 low dose levetiracetam extended release formulation can reduce abnormal hyperfunctional activity in the hippocampus in normal, healthy adults. The investigators will compare the functional connectivity results after taking AGB101 or placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAPOE 4
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMar 2018
Enrollment StartApr 2019
Primary CompletionMar 2021
TodayJul 2026
First PostedMar 12, 2018
Enrollment StartApr 11, 2019
Primary CompletionMar 31, 2021
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 8.3 years ago
Interventions
AGB101 220 mgdrug
AGB101 oral dose of 220 mg/day capsule, given as once-daily dosing.
Placeboother
Placebo, oral capsule given once-daily.